BioMed Research International / 2015 / Article / Tab 2

Review Article

Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors

Table 2

Emetogenic potential of oral antineoplastic agents most used in solid tumors (based on NCCN guidelines 2014).

NCCN guidelines 2014
Degree of emetogenicity (incidence)Agent

Moderate to highHexamethylmelamine
Crizotinib
Cyclophosphamide (≥100 mg/m2/day)
Estramustine
Etoposide
Lomustine (single day)
Mitotane
Procarbazine
Temozolomide (>75 mg/m2/day)
Vismodegib

Minimal to lowAxitinib
Cabozantinib
Capecitabine
Cyclophosphamide (<100 mg/m2/day)
Dabrafenib
Erlotinib
Everolimus
Gefitinib
Imatinib
Lapatinib
Methotrexate
Pazopanib
Regorafenib
Sorafenib
Sunitinib
Temozolomide (<75 mg/m2/day)
Topotecan
Trametinib
Vandetanib
Vemurafenib

You are browsing a BETA version of Hindawi.com. Click here to switch back to the original design.